KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in early Non-Small Cell Lung Cancer

Ella A. Eklund[1,2,3], Ali Mourad[1,2], Clotilde Wiel[1,2], Henrik Fagman[4,5], Andreas Hallqvist [3,7], Volkan I. Sayin[1,2]

[1]Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; [2]Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; [3]Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; [4]Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; [5]Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden; [6]Department of Microbiology and Immunology, Institute for Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; [7]Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden

Correspondence to:

V.I.S volkan.sayin@wlab.gu.se

Keywords: lung cancer, *KRAS*, tumor size

[1] Abbreviations

Word count: 3318

[1]List of abbreviations: ECOG: Eastern Cooperative Oncology Group; NSCLC: Non-Small Cell Lung Cancer; NGS: Next Generation Sequencing; PS: Performance Status; OS: Overall Survival; CT: Computed Tomography

Simple Summary

In this retrospective study including 310 patients with early (Stage I-II) non-small cell lung cancer (NSCLC), we investigated weather *KRAS* mutational status in combination with primary tumor size at diagnosis had any impact on clinical outcome. First, we analysed overall survival of patients grouped based on absence ($KRAS^{WT}$) or presence ($KRAS^{MUT}$) of mutations in *KRAS*. Next, we assessed risk of death when combining *KRAS* mutational status and tumor size. We found that $KRAS^{MUT}$ in combination with tumor size did not increase the risk of death.

Abstract

***Purpose*:** The aim of this study it to investigate the combined impact of *KRAS* mutational status and tumor size on overall survival and risk of death in stage I and II NSCLC.

***Methods*:** All consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage I-II NSCLC in the region of West Sweden were included in this multi-center retrospective study. Primary study outcome was overall survival (OS) and risk of death (HR).

***Results*:** Out of 310 Stage I-II NSCLC patients, 37% harbored an activating mutation in the *KRAS* gene ($KRAS^{MUT}$). Our study confirmed staging and tumor size as prognostic factors. *KRAS* mutational status was not found to impact overall survival and no difference in risk of death was observed when combining *KRAS* mutational status and primary tumor size.

***Conclusions*:** *KRAS* mutations in combination with primary tumor size are not associated with a worse prognosis in stage I and II NSCLC.

Background

Non-small cell lung cancer (NSCLC) is the second most common cancer worldwide (after breast cancer/prostate), with 2.1 million new cases and the highest mortality rate, causing 1.8 million deaths annually [1]. Staging is a crucial aspect of NSCLC management, as it is one of

the most important predictors of survival. The TNM staging system is used, which describes key tumor characteristics such as size, location and whether the disease has spread to lymph nodes and/or distant organs [2-5]. There are four main stages in NSCLC (stage I-IV), with stage IV having the worst prognosis. Early (stage I-IIIA) and advanced (stage IIIB-IV) are usually grouped together as early stages can be treated by management of the primary tumor. Pathological stage is considered the most important prognostic factor for resected patients, with 5-year survival rates of 83% for stage pIA, 71% for pIB, 57% for pIIA, 49% for pIIB, 36% for pIIIA and 23% for pIIIB [4]. The grouping early stage (I-II), advanced (III) and metastasized (IV) can be disputed to be more accurate due to that stage I-II is primary based on tumor size whereas a spread to the lymph nodes, a negative prognostic factor, is more common in stage III [3, 6].

Primary tumor size is an established factor in prognosis, with larger tumors associated with poorer survival [6-10]. The reason for this association is not yet fully understood but it is believed that larger tumors are more resistant to therapy due to having poorer blood supply, a different metabolism and potentially a higher likelihood of micrometastatic disease compared to smaller tumors. [11-14]. Further research is needed to elucidate this mechanism.

During the last decade, NSCLC treatment has increasingly depended on molecular profiling given the introduction of small molecule kinase inhibitors (SMKIs) targeting activating mutations in *EGFR, ALK, BRAF, RET, MET, NTRK* and *ROS1* oncogenes and with additional molecular targets pending approval [15]. While only around a third of patients harbour these mutations, the most frequent oncogenic driver in NSCLC is the Kirsten rat sarcoma viral oncogene (*KRAS*) present in up to 40% of all cases, with the most common mutations being G12C, G12V and G12D [16]. *KRAS* mutations have been associated with a worse outcome, both when treated with chemotherapy and radiotherapy, with shorter OS in stage III and IV patients [17-24]. Earlier studies have also showed *KRAS* mutations to negatively influence the

prognosis of NSCLC in early stages [25-27]. Although the evidence are accumulating, there are still some debate about the prognostic value of *KRAS* mutation status, This could be explained with heterogenicity within the sub-mutations [6, 28]. General attempts to target mutant KRAS was for long unsuccessful [26, 29]. However, lately several inhibitors specifically binding mutant KRAS-G12C have been investigated in clinical trials, with Sotorasib being the first treatment to gain approval for adults with stage IV NSCLC harbouring a KRAS-G12C mutation as second-line therapy [29-33]. Approximately 40% of all *KRAS* mutations are G12C mutations. Nonetheless, as with other SMKIs, a heterogenous pattern of resistance to KRAS-G12C inhibition has already been observed [34-37].

Both primary tumor size and *KRAS* mutation status are considered independent prognostic factors. In the era of precision medicine, mutational status needs to be investigated together with other prognostic variables. To our knowledge, no one has investigated the combined impact of primary tumor size and *KRAS* mutational status on overall survival and the risk of death in stage I-II NSCLC. Thus, we ask whether *KRAS* mutational status in combination with tumor size may refine prognostic stratification of stage I and II NSCLC.

In Sweden, reflex testing for targetable alterations in NSCLC, including *KRAS* mutational status, has been widely implemented since 2015. By including all consecutive patients diagnosed with Stage I-II NSCLC and molecularly assessed between 2016-2018 in west Sweden, the current retrospective cohort study provides a unique real-world dataset for assessing the impact of *KRAS* mutations and primary tumor size.

105

106 **Materials and Methods**

107 ***Patient population***

108 We conducted a multi-center retrospective study including all consecutive NSCLC patients
109 diagnosed with Stage I-II NSCLC and having molecular assessment performed between
110 2016-2018 in the Region Västra Götaland (region of West Sweden), Sweden (*n* = 310).
111 Further inclusion criteria was that tumor size from CT scan or pathology report had to be
112 available, as well as available follow-up data. Patients who were diagnosed before 2016,
113 had no digitally accessible patient chart, had no tumor measurements noted in the patient
114 chart or had a recurrent disease were excluded.

115

116 During this period, patients diagnosed with squamous cell carcinoma were molecularly
117 assessed to a lesser extent. Patient demographics (including age, gender, Eastern
118 Cooperative Oncology Group (ECOG) performance status and smoking history), cancer
119 stage, pathological details (histology, mutation status including *KRAS* mutational status and
120 subtype), first-line treatment and outcome data were retrospectively collected from patient
121 charts and the Swedish Lung Cancer Registry. Approval from the Swedish Ethical Review
122 Authority (Dnr 2019-04771 and 2021-04987) was obtained prior to study commencement

123

124 ***Mutational status***

125 Patients were assessed with NGS for mutational status on DNA from FFPE blocks or
126 cytological smears using the Ion AmpliSeq™ Colon and Lung Cancer Panel v2 from Thermo
127 Fisher Scientific as a part of the diagnostic workup process at the Department of Clinical
128 Pathology at Sahlgrenska University Hospital, assessing hotspot mutations in *EGFR, BRAF,*
129 *KRAS* and *NRAS*. Until June 2017, *ALK*-fusions were assessed with immunohistochemistry
130 (IHC), and with fluorescence in situ hybridization (FISH) if positive or inconclusive IHC; ROS1
131 was analysed upon request with FISH. Thereafter, *ALK, ROS1* and *RET* fusions were

132 assessed on RNA using the Oncomine Solid Tumor Fusion Panel from Thermo Fisher
133 Scientific.

134 ***Tumour size***

135 To have the most recent, accurate and untreated primary tumor size, measurements were
136 collected from the radiology report of the CT scan performed before a final diagnosis of
137 NSCLC was established. In patient who underwent surgical resection, the actual primary
138 tumor size was also collected from the pathology report. The largest tumor diameter in
139 millimeter (mm) was collected.

140

141 ***Study objectives***

142 The primary outcome of this study was OS and risk of death, defined as the interval between
143 the date of first treatment and the date of death from any cause. Patients alive or lost to follow-
144 up at data cut of were censored at last contact. Median follow up time was estimated using
145 the reverse Kaplan-Meier method. We compared OS and risk of death stratified on $KRAS^{WT}$
146 and $KRAS^{MUT}$.

147

148 ***Statistical analysis***

149 Clinical characteristics were summarized using descriptive statistics and evaluated with
150 univariate analysis in table form. Survival was estimated using the Kaplan-Meier method. Log-
151 rank test was used to assess significant differences in OS between groups. To evaluate if
152 there was a significant difference in primary tumor size between *KRAS* mutated and *KRAS*
153 wildtype patients, Mann Whitney U-test was used. Cox proportional hazard regression was
154 conducted to measure the influence of tumor size on risk of death (hazard ratio) stratified on
155 *KRAS* mutational status. We defined an interaction term between tumor size and *KRAS*
156 mutational status to assess the combined impact on risk of death (hazard ratio). Statistical
157 significance was set at $p<0.05$ and no adjustments were made for multiple comparisons. Data

158 analysis was conducted using IBM SPSS Statistics version 27 and GraphPad Prism version
159 9.

160 **Results**

161 **Patients and tumor characteristics**

162 A total of 310 consecutive patients were diagnoses with stage I and II NSCLC during 2016-
163 2018 in West Sweden and for whom genetic data were available were all included in this
164 retrospective cohort study (Figure. 1). Of these patients, over a third (115, 37%) had a *KRAS*
165 mutation (Table 1A). The majority were female (187, 60.3%), with a median age of 70 years,
166 86 % were current or former smokers. A large majority of patients (285, 92%) had a good
167 Performance Status (PS) with low ECOG 0-1 at diagnosis (Table 1A). The proportion of N1
168 was low (18, 5,8%). Most of the NSCLCs were adenocarcinoma of the lung (281, 90.6%)
169 while squamous cell carcinoma cases were relatively low (11, 3.5%), which was expected
170 due to the selection of histological type for NGS assessment (Table 1A). When comparing
171 the baseline characteristics of $KRAS^{WT}$ with $KRAS^{MUT}$ patients, the *KRAS* mutated
172 population had more females, no squamous cell carcinoma, and a higher proportion of
173 current and former smokers (Table 1A).

174

175 The majority underwent surgical resection (273, 88%). Three patients did not receive any
176 treatment and was excluded in further survival analyses (Table 1B). Median follow up time
177 was 63 months (CI 95% [59.7-68.3]) and date of cut of 31-10-22.

178

179 **No significant difference in survival for patients stratified on *KRAS* mutations**

180 When comparing OS for all stage I-II patients stratified on *KRAS* mutational status no
181 significant difference were detected with mean (median not reached) OS 74 months for
182 $KRAS^{WT}$ vs 63 months for $KRAS^{MUT}$ (p = 0.847) (Supplemental Figure. 1A). When analyzing
183 resected patients, no significant difference was observed with a mean (median not reached)
184 OS 78 months for $KRAS^{WT}$ vs 65 months for $KRAS^{MUT}$ (p = 0.856) (Supplemental Figure. 1B)

185 We further stratified on stage showing a mean (median not reached) OS 73 months for
186 stage I vs OS 50 months for stage II (Figure. 2A). We then conducted the analysis
187 separately, showing a mean (median not reached) OS 78 months for stage I vs OS 46
188 months for stage II for *KRAS*^{WT} (Figure. 2B) and a mean (median not reached) OS 65
189 months for stage I vs OS 53 months for stage II *KRAS*^{MUT}(Figure. 2C).
190
191 When stratifying for *KRAS* mutational status separately on stage I and stage II patients, no
192 significant difference was observed for stage I with a mean (median not reached) OS 78
193 months for *KRAS*^{WT} vs 65 months for *KRAS*^{MUT} (p = 0.756) (Supplemental Figure. 2A) or
194 stage II median OS 47 months for *KRAS*^{WT} vs 53 months for *KRAS*^{MUT} (p = 0.654)
195 ((Supplemental Figure. 2B).
196
197 **T stages and mutational status**
198 We further analyzed the impact of T stage on survival and found that it correlated as
199 expected with mean OS 82 months for T1, 55 months for T2 and 46 months for T3 (p<0.001)
200 (Figure. 3A). The same trend was observed when separately analyzing *KRAS*^{WT} with mean
201 (median not reached) OS 83 months for T1, 53 months for T2 and 45 months for T2
202 (p<0.001) (Figure. 3B) and *KRAS*^{MUT} with mean OS 65 months for T1, 58 months for T2 and
203 48 months for T3 (p<0.023) (Figure. 3C).

204 ***KRAS* mutations are associated with smaller tumor size at diagnosis**
205 To evaluate the difference between primary tumor size on CT-scan at diagnosis stratified on
206 *KRAS* mutation status we used the Mann Whitney U-Test. The test revealed that *KRAS*^{MUT}
207 primary tumors were significantly smaller at diagnosis, with a median size of 20 mm (n =
208 115) vs *KRAS*^{WT} median size of 25 mm (n = 190) (p = 0.043) (Figure. 4A).
209 However, we did not observe any difference in median tumor size when looking at tumor
210 size as assessed in resected specimens, *KRAS*^{WT} median=22mm (n=171) vs *KRAS*^{MUT}
211 median = 21 mm (n=102) (p=0.16) (Figure. 4B).

Tumor size from CT-scan is associated with higher risk of death

We found that primary tumor size from CT-scans correlated significantly with an increased risk of death (HR 1.018, 95% CI [1.008-1.028], p < 0.001). When *KRAS*^{WT} and *KRAS*^{MUT} groups were analyzed separately, the *KRAS*^{WT} group showed a significantly increased risk of death (HR = 1.015, 95% CI [1.003-1.028], p = 0.018). The same was observed in the *KRAS*^{MUT} group (HR = 1.023, 95% CI [1.006, 1.040], p = 0.007).

Tumor size in resection specimens is associated with higher risk of death

When testing the correlation between primary tumor size as assessed in resection specimens and risk of death, we found a significantly increased risk of death (HR = 1.029, 95% CI [1.018-1.040], p = < 0.001). We then continued to test the risk separately for the *KRAS*^{WT} and *KRAS*^{MUT} groups. The *KRAS*^{WT} group showed a significantly increased risk of death (HR = 1.030, 95% CI [1.017, 1.044], p = < 0.001). The same was observed when testing the *KRAS*^{MUT} group (HR = 1.028, 95% CI [1.009-1.047], p = 0.004).

The combination of *KRAS* mutation and tumor size dose not impact the risk of death

To test if the combination of tumor size and *KRAS* mutational status impacts the risk of death we defined an interaction term including both variables. For primary tumor size from CT scan and *KRAS* mutational status no significant difference in risk of death was detected group (HR = 1.008, 95% CI [0.988-1.030], p = 0.428). The same trend was observed for primary size as assessed in resection specimens (HR = 0.9977, 95% CI [0.975-1.020], p = 0.807).

240

241 **Discussion**

242 In the era of precision medicine, we need to explore new multimodal variables for prognosis
243 assessments. As the mutational status nowadays is an important predictive and prognostic
244 factor in NSCLC and *KRAS* mutations are associated with a worse prognosis, this study aimed
245 to investigate the impact of primary tumor size combined with *KRAS* mutational status on
246 overall survival and the risk of death in patients with Stage I-II NSCLC.

247

248 This study included all consecutive patients diagnosed with Stage I-II NSCLC and molecularly
249 assessed between 2016-2018 in West Sweden. We choose to only investigate stage I and II
250 patients with the attempt to get a more specified population mainly dependent on tumor size.
251 Only 5.8 % of the patients had a N1 disease that could affect the prognosis. The majority of
252 patients had the tumor resected and more than 90% of tumors was adenocarcinoma. Thus,
253 this data can be argued to apply for stage I-II resected adenocarcinoma.

254

255 No significant difference was observed when comparing OS for all stage I-II patients stratified
256 on *KRAS* mutational status. However, the mean overall survival was 11 months shorter for
257 $KRAS^{MUT}$ patients. The same trend was observed when looking at resected patients with a 13
258 months shorter mean survival for $KRAS^{MUT}$. Our result could differ to former studies due to
259 them not being corrected for tumor size [25, 26].

260

261 We confirmed the impact of staging for prognosis showing a large difference in survival
262 between stage I and II patients. When analyzing the impact of T stage on survival, we found
263 that T stage correlated as expected with mean OS, with T1 having a better OS than T2 and
264 T3, confirming the impact of primary tumor size on OS. This correlation was also observed
265 when separately analyzing $KRAS^{WT}$ and $KRAS^{MUT}$ patients although the separation was not
266 as clear in $KRAS^{MUT}$ patients compared to $KRAS^{WT}$.

267

268 As expected, primary tumor size from CT scans and resection specimens was significantly
269 associated with an increased risk of death, and this correlation was observed in both *KRAS*^{MUT}
270 and *KRAS*^{WT} patients. However, when combining tumor size and *KRAS* mutational status
271 there was no increased risk of death.
272
273 The current study confirmed staging and tumor size as prognostic factors. *KRAS* mutational
274 status was not found to impact overall survival and no difference in risk of death was observed
275 when combining *KRAS* mutational status and tumor size. However, this study has not
276 assessed recurrence rate or progression free survival.
277
278 In summary, the study showed that *KRAS* mutational status did not significantly impact OS
279 and risk of death in stage I and II NSCLC patients. The current study provides a unique real-
280 world dataset for assessing the impact of *KRAS* mutations and tumor size. It is important
281 information to be used in future pooled analysis for prognosis assessments.
282
283
284 **Conclusion**
285 Here we confirm the importance of primary tumor size as a prognostic factor for survival in
286 stage I and II NSCLC. *KRAS* mutations were not found to impact overall survival and no
287 difference in risk of death was observed when combining *KRAS* mutations and primary tumor
288 size at diagnosis.
289
290
291 **Acknowledgements**
292 We thank Sayin lab members for critical reading of the manuscript. In addition, we thank
293 members of the of the Swedish Lung Cancer Registry, and the continuous reporting by
294 Swedish healthcare employees.
295

Funding

This work was supported by the Swedish Research Council (2018-02318 and 2022-00971 to VIS, 2021-03138 to CW), the Swedish Cancer Society (20-1278 to VIS, 22-0612FE to CW), the Gothenburg Society of Medicine (2019; 19/889991 to EAE), Assar Gabrielsson Research Foundation (to EAE, CW and VIS), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (to HF), Department of Oncology, Sahlgrenska University Hospital (to EAE and AH), the Swedish Society for Medical Research (2018; S18-034 to VIS) and the Knut and Alice Wallenberg Foundation and the Wallenberg Centre for Molecular and Translational Medicine (to VIS).

Declaration of potential conflict of interest

The authors have declared no conflicts of interest.

Institutional Review Board Statement

Approval from the Swedish Ethical Review Authority (Dnr 2019-04771 and 2021-04987) was obtained prior to the commencement of the study.

Informed Consent Statement:

Patient statement was not required due to the retrospective nature of this study.

Data Availability Statement

Data from this study is available upon reasonable request.

316 **References**

317

318 1. *World Health Organization, International Agency for Research on Cancer. Globocan*
319 *2020: Lung Cancer. International Agency for Research on Cancer. Available at*
320 *http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed:*
321 *March 2, 2021.*
322 2. Amin, M.B., et al., *The Eighth Edition AJCC Cancer Staging Manual: Continuing to*
323 *build a bridge from a population-based to a more "personalized" approach to cancer*
324 *staging.* CA Cancer J Clin, 2017. **67**(2): p. 93-99.
325 3. Detterbeck, F.C., *The eighth edition TNM stage classification for lung cancer: What*
326 *does it mean on main street?* J Thorac Cardiovasc Surg, 2018. **155**(1): p. 356-359.
327 4. Goldstraw, P., et al., *The IASLC Lung Cancer Staging Project: Proposals for Revision*
328 *of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM*
329 *Classification for Lung Cancer.* J Thorac Oncol, 2016. **11**(1): p. 39-51.
330 5. Wankhede, D., *Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A*
331 *Meta-analysis.* Ann Surg Oncol, 2021. **28**(1): p. 142-147.
332 6. Garinet, S., et al., *Updated Prognostic Factors in Localized NSCLC.* Cancers (Basel),
333 2022. **14**(6).
334 7. Chen, Y., et al., *Prognostic factors of survival in patients with non-small cell lung*
335 *cancer: a competing risk model using the SEER database.* Transl Cancer Res, 2022.
336 **11**(11): p. 3974-3985.
337 8. Gerber, D.E., et al., *Baseline tumour measurements predict survival in advanced non-*
338 *small cell lung cancer.* Br J Cancer, 2013. **109**(6): p. 1476-81.
339 9. Okada, M., et al., *Effect of tumor size on prognosis in patients with non-small cell*
340 *lung cancer: the role of segmentectomy as a type of lesser resection.* J Thorac
341 Cardiovasc Surg, 2005. **129**(1): p. 87-93.
342 10. Zhang, J., et al., *Relationship between tumor size and survival in non-small-cell lung*
343 *cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results*
344 *(SEER) registry.* J Thorac Oncol, 2015. **10**(4): p. 682-90.
345 11. Goldie, J.H. and A.J. Coldman, *A mathematic model for relating the drug sensitivity*
346 *of tumors to their spontaneous mutation rate.* Cancer treatment reports, 1979. **63**(11-
347 12): p. 1727-1733.
348 12. Skipper, H.E., *Thoughts on Cancer Chemotherapy and Combination Modality*
349 *Therapy (1974).* JAMA, 1974. **230**(7): p. 1033-1035.
350 13. Jain, R.K., *Physiological Barriers to Delivery of Monoclonal Antibodies and Other*
351 *Macromolecules in Tumors1.* Cancer Research, 1990. **50**(3_Supplement): p. 814s-
352 819s.
353 14. Trédan, O., et al., *Drug Resistance and the Solid Tumor Microenvironment.* JNCI:
354 Journal of the National Cancer Institute, 2007. **99**(19): p. 1441-1454.
355 15. König, D., S. Savic Prince, and S.I. Rothschild, *Targeted Therapy in Advanced and*
356 *Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most*
357 *Important Actionable Oncogenic Driver Alterations.* Cancers (Basel), 2021. **13**(4).
358 16. Tartarone, A., et al., *Beyond Conventional: The New Horizon of Targeted Therapy for*
359 *the Treatment of Advanced Non Small Cell Lung Cancer.* Front Oncol, 2021. **11**: p.
360 632256.
361 17. Brady, A.K., et al., *Survival outcome according to KRAS mutation status in newly*
362 *diagnosed patients with stage IV non-small cell lung cancer treated with platinum*
363 *doublet chemotherapy.* Oncotarget, 2015. **6**(30): p. 30287-94.

18. Eklund, E.A., et al., *KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.* Cancers (Basel), 2022. **14**(9).
19. Goulding, R.E., et al., *KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.* Cancer Treat Res Commun, 2020. **24**: p. 100200.
20. Hallqvist, A., et al., *Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy.* Lung Cancer Int, 2012. **2012**: p. 587424.
21. Hames, M.L., et al., *Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.* Lung Cancer, 2016. **92**: p. 29-34.
22. Marabese, M., et al., *KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.* Oncotarget, 2015. **6**(32): p. 34014-22.
23. Mellema, W.W., et al., *KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.* J Thorac Oncol, 2013. **8**(9): p. 1190-5.
24. Rodenhuis, S., et al., *Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.* J Clin Oncol, 1997. **15**(1): p. 285-91.
25. Meng, D., et al., *Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.* Lung Cancer, 2013. **81**(1): p. 1-10.
26. Kadota, K., et al., *KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.* Am J Surg Pathol, 2016. **40**(12): p. 1579-1590.
27. Izar, B., et al., *The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.* J Thorac Oncol, 2014. **9**(9): p. 1363-9.
28. Ihle, N.T., et al., *Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.* J Natl Cancer Inst, 2012. **104**(3): p. 228-39.
29. Burns, T.F., et al., *Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.* J Clin Oncol, 2020. **38**(35): p. 4208-4218.
30. Addeo, A., G.L. Banna, and A. Friedlaender, *KRAS G12C Mutations in NSCLC: From Target to Resistance.* Cancers (Basel), 2021. **13**(11).
31. Indini, A., et al., *Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.* Pharmaceutics, 2021. **13**(5).
32. Mathieu, M., et al., *KRAS G12C fragment screening renders new binding pockets.* Small GTPases, 2021: p. 1-14.
33. Skoulidis, F., et al., *Sotorasib for Lung Cancers with KRAS p.G12C Mutation.* N Engl J Med, 2021.
34. Fakih, M.G., et al., *Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.* Lancet Oncol, 2022. **23**(1): p. 115-124.
35. Ho, C.S.L., et al., *HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2.* Eur J Cancer, 2021. **159**: p. 16-23.
36. Sattler, M., et al., *Precision oncology provides opportunities for targeting KRAS-inhibitor resistance.* Trends Cancer, 2023. **9**(1): p. 42-54.

37. Zhao, Y., et al., *Diverse alterations associated with resistance to KRAS(G12C) inhibition.* Nature, 2021. **599**(7886): p. 679-683.

Figure legends

Table 1A Characteristics of the total cohort as well as stratified on *KRAS*^{WT} and *KRAS*^{MUT}.

Data are presented as n (%).

ECOG PS, Eastern Cooperative Oncology Group Performance Status. T, Tumor. N, Nodulus.

Table 1B Summery of first line treatment of the total cohort as well as stratified on *KRAS*^{WT} and *KRAS*^{MUT}. Data are presented as n (%).

Figure 1. Patient selection

Flow chart showing the patient selection for the study.

Figure 2. Staging impacts overall survival

A. Kaplan-Meier estimates comparing overall survival for the full cohort stratified on stage I and stage II.

B. Kaplan-Meier estimates comparing overall survival for *KRAS*^{WT} patients stratified on stage I and stage II.

B. Kaplan-Meier estimates comparing overall survival for *KRAS*^{MUT} patients stratified on stage I and stage II.

Figure 3. Primary tumor size impacts overall survival

A. Kaplan-Meier estimates comparing overall survival for the full cohort stratified on T1, T2 and T3.

B. Kaplan-Meier estimates comparing overall survival for *KRAS*^{WT} patients stratified on T1, T2 and T3.

443 **C.** Kaplan-Meier estimates comparing overall survival for *KRAS*^{MUT} patients stratified on T1,
444 T2 and T3.
445

446 **Figure 4. *KRAS* mutation is associated with smaller tumor size at diagnosis**

447 **A.** Primary tumor size from CT-scan in mm.
448 **B.** Primary tumor size from resection specimens in mm.
449
450

451 **Supplemental Figure 1**

452 **A.** Kaplan-Meier estimates comparing overall survival for the full cohort stratified KRAS
453 mutational status.
454 **B.** Kaplan-Meier estimates comparing overall survival for the resected patients stratified
455 *KRAS* mutational status.
456

457 **Supplemental Figure 2**

458 **A.** Kaplan-Meier estimates comparing overall survival for stage I patients stratified by *KRAS*
459 mutational status.
460

461 **B.** Kaplan-Meier estimates comparing overall survival for stage II patients stratified by *KRAS*
462 mutational status.
463

Eklund et al. Figure 1



Table 1A

Characteristics all patients stage I-II NSCLC	**Total**	***KRAS* WT**	***KRAS* MUT**
	n (%)	n (%)	n (%)
Total	310 (100)	195 (63.0)	115 (37.0)
Age in years, median (range)	70 (35-85)	70 (35-85)	70 (48-84)
Sex			
Male	123 (39.7)	88 (45.1)	35 (30.4)
Female	187 (60.3)	107 (54.9)	80 (69.6)
Smoking history			
Current smoker	99 (31.9)	51 (26.2)	48 (41.7)
Former smoker	168 (54.2)	106 (54.4)	62 (53.9)
Never smoker	43 (13.9)	38 (19.5)	5 (4.3)
Perfomance status			
ECOG 0	144 (46.5)	82 (42.1)	62 (53.9)
ECOG 1	141 (45.5)	96 (49.2)	45 (39.1)
ECOG 2	24 (7.7)	16 (8.2)	8 (7.0)
ECOG 3	1 (0.3)	1 (0.5)	0
ECOG 4	0	0	0
Histology			
Adenocarcinoma	281 (90.6)	168 (86.2)	113 (98.3)
Squamous cell carcinoma	11 (3.5)	11(5.6)	0
NCSLC NOS	18 (5.9)	16 (8.2)	2 (1.7)
Mutation status			
None known	124 (40.2)	124 (63.6)	
KRAS	115 (37.0)		
EGFR	54 (17.4)	54 (27.7)	
BRAF	6 (1.9)	6 (3.1)	
ALK	4 (1.3)	4 (2.1)	
ROS1	3 (1.0)	3 (1.5)	
RET	1 (0.3)	1 (0.5)	
Other	3 (1.0)	3 (1.5)	
KRAS submutation			
G12A			9 (7.8)
G12C			54 (47.0)
G12D			15 (13.0)
G12S			1 (0.9)
G12V			26 (22.6)
G13C			2 (1.7)
G13D			1 (0.9)
Q61H			4 (3.5)
Q61L			3 (2.6)
TNM			
T1a	99 (31.9)	55 (28.2)	44 (38.3)
T1b	76 (24.5)	54 (27.7)	22 (19.1)
T1c	12 (3.9)	7 (3.6)	5 (4.3)
T2a	67 (21.6)	46 (23.6)	21 (18.3)
T2b	28 (9.0)	15 (7.8)	13 (11.3)
T3	28 (9.0)	18 (9.2)	10 (8.7)
N0	292 (94.2)	185 (94.9)	107 (93.0)
N1	18 (5.8)	10 (5.1)	8 (7.0)
Measurement modality			
CT-scan (mm)	305 (98.4)	190 (97.4)	115 (100)
PAD	273 (88.0)	171 (88.7)	102 (88.7)
At last follow up 31/10-2022			
Alive	206 (66.5)	128 (65.6)	78 (67.8)
Deceased	104 (33.5)	67 (34.4)	37 (32.2)
Survival			
Mean survival (months)	63	62	64

Table 1B

Treatment table all patients stage I-II NSCLC	**Total**	***KRAS* WT**	***KRAS* MUT**
	n (%)	n (%)	n (%)
Total	310 (100)	195 (63.0)	115 (37.0)
Surgery	273 (88.0)	171 (87.7)	102 (88.7)
Curative chemoradiotherapy	7 (2.3)	6 (3.1)	1 (0.9)
Medical treatment	2 (0.6)	1 (0.5)	1 (0.9)
Stereotactic radiotherapy	11 (3.5)	11 (5.6)	0 (0)
Radiotherapy	14 (4,5)	3 (1,5)	11 (9.6)
No treatment	3 (1.0)	3 (1.5)	0 (0)

Eklund et al. Figure 2



Eklund et al. Figure 3



Eklund et al. Figure 4



Eklund et al. Supplemental Figure 1





Eklund et al. Supplemental Figure 2